Nonalcoholic steatohepatitis (NASH ... This article will briefly discuss prevalence studies and the pathophysiology of NAFLD and focus on current discussions related to the specific lesions ...
Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated with significant global public health concerns. It is prevalent in 30% of ...
AI-powered digital pathology specialist PathAI, based in Boston in the US, said that AIM-NASH AI Assist is designed to assist ...
Hosted on MSN19d
Researchers identify a gene to guide novel therapeutics of nonalcoholic fatty liver diseasesMore information: Rui Zuo et al, Ablation of Hepatic Asah1 Gene Disrupts Hepatic Lipid Homeostasis and Promotes Fibrotic Nonalcoholic Steatohepatitis in Mice, The American Journal of Pathology (2024).
Histoindex Pte Ltd. launched its laboratory-developed test for metabolic dysfunction-associated steatohepatitis (MASH), ...
DelveInsight’s, “Nonalcoholic Steatohepatitis Pipeline Insight” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Nonalcoholic Steatohepatitis pipeline ...
HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the ...
The biopsy findings of cirrhotic NAFLD and NASH are another area of investigation in pathology ... retain diagnostic histopathologic features of steatohepatitis in follow-up biopsy, which provides ...
Metabolic dysfunction-associated steatohepatitis (MASH) is a polygenic disorder influenced by multiple genes, but their ...
Metabolic dysfunction-associated steatohepatitis (MASH ... A key factor in the pathology of MASH is the disruption of endoplasmic reticulum (ER) homeostasis. The ER stores calcium ions (Ca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback